Welcome
The Opportunity

A New Revenue Stream Inside Every Mammography Appointment

Cortex is a software upgrade to existing mammography hardware that adds wrist bone density assessment, completed during the scan and billed directly to the patient.

This short pre-read walks you through how it works, what patients have told us, and the economics — before a brief set of questions about the commercial model.

How your responses will be used

Your feedback will be used by the Cortex team to refine the commercial model and bring bone health assessment into routine mammography workflows. Responses are reviewed in aggregate. We will not share your individual responses with third parties for marketing, and you may stop at any time. Please choose the level of consent you are comfortable with below.

Your consent *

Your information will be processed in accordance with the IBEX Innovations Privacy Notice.

This field is required.
This field is required.
This field is required.

The Cortex Patient Story

A short explainer on what the Cortex assessment looks like from the patient's perspective.

Patient explainer video

Implementation & Workflow

Cortex is added through software, screened during the existing visit, and billed directly to the patient — with no insurance coding or reimbursement cycle.

Step 1 — Upgrade
01

Software Deployed to Your Mammography Hardware

We work directly with your mammography hardware provider. No new hardware. Pay-per-use.

Step 2 — Screen
02

Wrist Assessment During the Mammography Visit

The bone density measurement is a quick exposure of the wrist with minimal impact on gantry-time.

Step 3 — Bill
03

Instant Report. Direct Patient Billing at $99.

Payment is collected at point of care — cash-pay, no insurance coding, no prior authorisation, no reimbursement cycle.

What patients told us

I would just like to say I love this idea so very much. Many people are underinformed and don't know anything about how important bone health is.

Survey respondent aged 44 · shown $99 pricing

98%
of women 40–65 said they are likely or very likely to request a Cortex assessment with their next mammogram
$99
65% shown the $99 price believed this was good or fair value as a cash-pay add-on
30%
provided their contact details to be notified when Cortex becomes available in the US

Cortex Consumer Survey · N=198

Revenue Projection

Adjust the inputs for your own practice to see the estimated uplift. Defaults reflect a facility performing 10,000 mammograms per year.

%
$
%
$
Uplift per Mammography Appointment
80%
Example $99 cash-pay added to a $124 mammography billing rate.
Estimated Annual Gross Revenue
$695,000
Cortex cash-pay plus downstream DXA follow-up revenue.
A note on focus. This questionnaire is purely commercial and business-model oriented. We fully recognise that clinical efficacy and patient outcomes are the foundation of any new service, and robust, peer-reviewed trial data is available but out of scope here. For this exercise, please focus on the business model and workflow logistics.
Target demographic. Cortex is positioned for women aged 40–65 undergoing routine screening mammography. Please keep this specific population in mind as you answer.

Institutional Overview & Demographics

Helps us understand your clinical volume and how you make new technology purchasing decisions.

1.Approximately how many mammograms does your health system or facility perform per year?

2.How much additional net revenue would an assessment need to generate per patient to justify increasing the mammography appointment window by 2 minutes?

3.Is secondary revenue considered when making a buying decision on new technology?

By secondary revenue, we mean downstream revenue generated from follow-ups on positive results within this 40–65 female demographic, such as diagnostic DEXA scans or specialist referrals.

If yes — when does secondary revenue become a meaningful factor in your executive decision-making?

4.Is providing patients with access to the latest technology part of your institution's patient value proposition?

Clinical Proposition & Workflow Integration

How Cortex fits into your existing patient care model and operational workflow.

5.Assuming an out-of-pocket patient self-pay fee of $99 (with insurance reimbursement anticipated at a later stage), what is the maximum amount of additional technologist time that could be allocated per patient to deliver this service?

6.While consumer surveys indicate strong patient intent to opt-in, real-world adoption can vary. What do you realistically believe the actual patient adoption rate would be among eligible women aged 40–65 within your practice?

Market Differentiation & Financial Impact

The strategic and competitive value of the service to your organisation.

7.If you were the sole provider of Cortex in your local market, do you believe this would impact choice of imaging facility among women aged 40–65?

8.Would the availability of Cortex integration influence your choice of mammography hardware system provider?

9.Would the availability of Cortex integration bring forward a planned capital hardware procurement?

Pricing & Decision Making

10.Taking into account your facility's internal delivery, IT integration, and operational costs, what price per assessment charged to your institution by the Cortex software provider represents:

Good value
$
per assessment
A fair price
$
per assessment
Unaffordable
$
per assessment

11.How likely would you be to offer Cortex to your target patient base (women 40–65) if it were available at the "fair price" you indicated in question 10?

12.What further financial, operational, or IT integration information would you require to make a final purchasing decision?

13.Do you have any additional comments you would like to make?

Thank you for completing this brief survey. Your feedback will help us bring Cortex bone health assessment into routine mammography workflows.

Thank you

Your responses have been recorded. We appreciate you taking the time to share your perspective on the Cortex commercial model — it directly shapes how we bring this to providers.